Galenical form for the administration of triptans by buccal transmucous means
OwnerPhilippe Perovitch, Marc Mauryinventors
Life of this patent
Estimating the term…
Abstract
A galenical form for the buccal transmucous administration of at least one active ingredient of the triptan family, includes at least: the active ingredient in basic form and in salt form, and a hydro-alcoholic solution that titrates at least 15 degrees of alcohol, whereby the active ingredient is present in a stable and complete state of dissolution in the hydro-alcoholic solution so as to allow a fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for the production of this galenical formulation as well as its use are described.
Claims17
A galenical form for buccal transmucous administration of at least one active ingredient of the triptan family, comprising:
- said active ingredient in a combination of a basic form and a salt form, and
- a solvent, said solvent consisting of a hydro-alcoholic solution of water and ethanol, the water content being between 15% and 70% by mass and the ethanol content being between 30% and 85% by mass, said hydro-alcoholic solution being the sole solvent,
- wherein the galenical form contains between 0.5 and 6 mg of said active ingredient in less than 5 ml of the solvent, and
- whereby said active ingredient is present in a stable and complete state of dissolution in the solvent so as to allow fast absorption of all of said active ingredient through mucous membranes of a buccal cavity, wherein the mucous membranes are the gingival and/or jugal mucous membranes.
A pharmaceutical composition for treating a migraine attack, comprising:
- sumatriptan, in a combination of a basic form and a salt form;
- and
- a solvent, said solvent consisting of a hydro-alcoholic solution of water and ethanol, the water content being between 15%-70% by mass and the ethanol content being between 30%-85% by mass, the hydro-alcoholic solution being the sole solvent of the sumatriptan,
- wherein the composition is in a form for buccal transmucous administration to a subject and comprises 0.1-6 mg sumatriptan per ml solvent.
Dependencies are inferred from the claim text.